GGrantIndex
Sort

53,477 grants matching addiction

Project 1

$766,758
Bruce W Stillman · Cold Spring Harbor Laboratory · P01 · FY2017 · CA

Neuroimaging response inhibition and salience attribution changes during mindfulness-based treatment of human heroin addiction

$766,743
Rita Z Goldstein · Icahn School Of Medicine At Mount Sinai · R01 · FY2019 · AT

Treatment of Chemotherapy-Induced Peripheral Neuropathy via Genetic Repression of Sodium Channels

$766,685
Fernando Aleman Guillen · Navega Therapeutics, Inc. · R44 · FY2021 · CA

Using Sleep Health to Optimize Smoking Cessation Treatment Response in HIV-Positive Adults

$766,569
Elizabeth Connick · University Of Arizona · R01 · FY2022 · DA

Phase 2 Selective DAT inhibitor for treatment of Obesity.

$766,488
Frank Zemlan · P2d, Inc. · R44 · FY2011 · DK

Services Research: Psychiatric Comorbidity in Drug Abuse

$766,390
Johns Hopkins University · R01 · FY2003 · DA

Clinical Core

$766,360
Henry Richard Kranzler · University Of Pennsylvania · P30 · FY2020 · DA

Clinical Trials Network: The Texas Node

$766,319
Madhukar H Trivedi · Ut Southwestern Medical Center · UG1 · FY2019 · DA

Clinical Trials Network: The Texas Node

$766,319
Madhukar H Trivedi · Ut Southwestern Medical Center · UG1 · FY2018 · DA

Vancouver Drug Users Study: Evaluating the Natural History of Injection Drug Use

$766,270
Thomas Kerr · University Of British Columbia · U01 · FY2015 · DA

Endocannabinoid roles in neurochemical and reinforcing effects of abused drugs

$766,152
Gianluigi Tanda · National Institute On Drug Abuse · ZIA · FY2018 · DA

Drug Abuse Training Program

$766,040
Jacqueline F. McGinty · Medical University Of South Carolina · T32 · FY2020 · DA

Multi-modal profiling of spatially resolved cell types mediating opioid withdrawal

$765,953
Xiaoke Chen · Stanford University · R01 · FY2023 · DA

cART, neuroHIV, cocaine abuse and the mPFC neuron/astrocyte dysfunction

$765,908
Xiu-Ti Hu · Rush University Medical Center · R01 · FY2023 · DA

Enhancing Substance Use Treatment Services to Decrease Dropout and Improve Outpatient Treatment Utilization in Emerging Adults

$765,718
Kristyn Zajac · University Of Connecticut Sch Of Med/Dnt · R01 · FY2021 · DA

Context and Subjective Experience Surrounding Dual Cigarette and E Cigarette Use

$765,564
Robin J Mermelstein · University Of Illinois At Chicago · R01 · FY2019 · CA

Endocannabinoid roles in neurochemical and reinforcing effects of abused drugs

$765,562
Gianluigi Tanda · National Institute On Drug Abuse · ZIA · FY2017 · DA

Evaluation of Clinical Effectiveness, Cost, and Implementation Factors to Optimize Scalability of Treatment for Co-Occurring SUD and PTSD Among Teens

$765,488
Carla Kmett Danielson · Medical University Of South Carolina · R01 · FY2021 · DA

Cherokee Nation Prevention Trial: Interactive Effects of Environment & SBIRT

$765,466
Kelli Ann Komro · University Of Florida · R01 · FY2012 · AA

Novel PET imaging agents for understanding glutamine addiction in cancer

$765,328
Hank F Kung · University Of Pennsylvania · R01 · FY2013 · CA

Data Core

$765,040
Mingyao Li · University Of Pennsylvania · U19 · FY2023 · NS

Optimization and preclinical development of FAAH inhibitors for smoking cessation

$765,000
Daniele Piomelli · University Of California-Irvine · DP1 · FY2010 · DA

Core Center for Translational Addiction Sciences

$765,000
Kathryn A. Cunningham · University Of Texas Med Br Galveston · P30 · FY2010 · DA

Core Center for Translational Addiction Sciences

$765,000
Kathryn A. Cunningham · University Of Texas Med Br Galveston · P30 · FY2009 · DA

Clinical Laboratory Core

$764,901
Jennifer W Tidey · Brown University · P20 · FY2019 · GM